Savoy S M, Gianino J M
Rehabil Nurs. 1993 Mar-Apr;18(2):105-13. doi: 10.1002/j.2048-7940.1993.tb00731.x.
Severe and disabling spasticity frequently occurs in people with multiple sclerosis and spinal cord injury. Approximately 30% of these people are treated with oral antispasmodic medications that do not provide adequate relief from spasticity (Hattab, 1980). Clinical trials with spinal stimulation and ablative neurosurgical procedures have not been as uniformly successful for controlling spasticity as has intrathecal baclofen injection (Kasdon, 1986). Delivered by an implantable programmable drug pump, intrathecal baclofen injection has proven to be successful in treating individuals with intractable spasticity. Significant reduction in muscle tone and frequency of spasms have contributed to improved function with activities of daily living, bladder management, overall comfort, and quality of sleep (Penn et al., 1989; Parke, Penn, Savoy, & Corcos, 1989). This article introduces an innovative therapy for controlling spasticity and discusses the nurse's role in patient selection and management.
严重且致残的痉挛经常发生在多发性硬化症和脊髓损伤患者身上。这些患者中约有30%接受口服抗痉挛药物治疗，但这些药物并不能充分缓解痉挛（哈塔卜，1980年）。与鞘内注射巴氯芬相比，脊髓刺激和切除性神经外科手术在控制痉挛方面的临床试验并不总是同样成功（卡斯登，1986年）。鞘内注射巴氯芬通过植入式可编程药物泵给药，已被证明在治疗顽固性痉挛患者方面是成功的。肌张力和痉挛频率的显著降低有助于改善日常生活活动、膀胱管理、整体舒适度和睡眠质量（佩恩等人，1989年；帕克、佩恩、萨沃伊和科尔科斯，1989年）。本文介绍了一种控制痉挛的创新疗法，并讨论了护士在患者选择和管理中的作用。
